Triple-Negative Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Erika Hamilton, Prof Sherene Loi, Dr Mark E Robson and Dr Hope S Rugo. Introduction Program Overview: Dr Love (00:00) Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making Case (Dr Loi): A woman in her early 40s with PD-L1-positive metastatic TNBC (mTNBC) and a germline BRCA mutation (01:11) Case (Dr Robson): A woman in her early 40s with PD-L1-positive mTNBC experiences disease progression on atezolizumab/nab paclitaxel and is considering next steps (09:29) Faculty Presentation: Dr Hamilton (14:16) Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC Case (Dr Hamilton): A woman in her mid-50s with mTNBC achieves a complete response to atezolizumab/nab paclitaxel on the IMpassion130 trial (26:59) Faculty Presentation: Dr Rugo (34:22) Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC          Case (Dr Rugo): A woman in her early 30s with TNBC and a BRCA1 mutation has extensive residual disease after neoadjuvant chemotherapy and receives olaparib (54:25) Case (Dr Hamilton): A woman in her early 60s with mTNBC and a germline BRCA2 mutation experiences gastrointestinal toxicities and cytopenias while receiving olaparib (56:28) Faculty Presentation: Dr Robson (58:34) Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials Case (Dr Rugo): A woman in her late 50s with TNBC experiences prolonged stable disease after receiving adjuvant capecitabine followed by pembrolizumab (1:11:49) Case (Dr Robson): A woman in her early 40s initially diagnosed with TNBC and a germline BRCA mutation presents 8 years later with node-positive contralateral TNBC (1:14:53) Faculty Presentation: Prof Loi (1:19:45) CME information and select publications